TABLE 3.

Incremental Costs and Benefits and Cost-Effectiveness Ratio for the Current Policy Compared With No Screening and No PN

Scenario	Cumulative Costs in '000s (Discounted) ($)	Cumulative QALYs Lost in '000s (Discounted)	Incremental Costs, in ‘000s ($)	Incremental QALYs Gained, in ‘000s	ICER ($/QALY Gained)
1. 2000–2015
No screening and no PN*	15,969,000	1908.90	NA	NA	NA
Current policy†	21,157,000	1374.10	5,188,000	534.80	9700.8
95% Uncertainty	NA	NA	−270,670; 11,369,000	157.35; 1176.8	Cost-saving; 49,478
2.1. 2016–2019
Current Policy†	6,919,100	349.96	NA	NA	NA
Guidelines‡	8,042,900	311.93	1,123,800	38.030	29,550
95% Uncertainty	NA	NA	416,440; 1,938,200	11.383; 82.157	7832.8; 117,210
2.2. 2016–2019 + 5 y
Current policy†	14,541,000	738.34	NA	NA	NA
Guidelines‡	15,494,000	681.35	953,000	56.990	16,722
95% Uncertainty	NA	NA	202,170; 1,785,400	16.844; 124.58	2511.4; 73,877

Costs are in $2000 US dollars. All results are shown to 5 significant digits.

*No screening and no physician-initiated PN for 2000–2015.

^†Screening coverage and PN for 2000–2015 were as estimated in the calibrated model.² For scenarios 2.1 and 2.2, screening uptake in year 2016 and beyond was assumed to be the same as the calibrated model estimate for 2015.

^‡In screening by guidelines: all sexually-active women aged 15–24 years are screened annually, and screening coverage of women 25 years and older is the same as in the “current policy” scenario. For scenario 2.2: for years 2020–2024 screening coverage as estimated in the model in 2015.